🎉 M&A multiples are live!
Check it out!
Company | Headquarters | Sector | Stock Price | Enterprise Value | EV/Revenue | EV/EBITDA |
---|---|---|---|---|---|---|
AstraZeneca | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £100 | $224B | 4.0x | 11.9x |
GSK | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics, Vaccines & Immunotherapies | £13 | $84.6B | 2.1x | 5.9x |
Haleon | United Kingdom of Great Britain and Northern Ireland | Health & Beauty, Drug Development & Therapeutics | £4 | $53.7B | 3.7x | 14.7x |
Hikma Pharmaceuticals | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £18 | $6.3B | 2.0x | 7.5x |
Genus | United Kingdom of Great Britain and Northern Ireland | Agriculture, Genomics & Personalized Medicine, Bioindustrials | £16 | $1.7B | 1.9x | 11.4x |
HUTCHMED | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £2 | $1.5B | 2.4x | -65.8x |
Indivior | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £7 | $1.2B | 1.0x | 4.0x |
Oxford Nanopore | United Kingdom of Great Britain and Northern Ireland | Pharma Diagnostics & Analytics, Medical Devices | £1 | $1.0B | 4.3x | -7.4x |
Alliance Pharma | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Health & Beauty, Nutraceuticals & Cosmeceuticals | £1 | $528M | 2.2x | 9.3x |
Oxford BioMedica | United Kingdom of Great Britain and Northern Ireland | Contract Research & Manufacturing, Drug Development & Therapeutics | £3 | $443M | 2.5x | -32.9x |
Allergy Therapuetics | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £0 | $352M | 4.8x | -13.7x |
Faron Pharmaceuticals | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £2 | $341M | 90.4x | -18.9x |
International Biotechnology Trust | United Kingdom of Great Britain and Northern Ireland | Private Equity, Asset Management | £5 | $263M | N/A | N/A |
4basebio | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Genomics & Personalized Medicine | £12 | $240M | 113.0x | -15.8x |
Avacta Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Pharma Diagnostics & Analytics | £0 | $169M | 6.4x | -5.7x |
Bioventix | United Kingdom of Great Britain and Northern Ireland | Pharma Diagnostics & Analytics | £25 | $158M | 9.1x | 11.8x |
Animalcare Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £2 | $150M | 1.5x | 8.6x |
MaxCyte | United Kingdom of Great Britain and Northern Ireland | Medical Devices, Drug Development & Therapeutics | £2 | $124M | 3.2x | -3.5x |
Scancell | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £0 | $118M | 17.0x | -7.7x |
Shield Therapeutics | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £0 | $48.0M | 1.3x | -2.5x |
Futura Medical | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £0 | $33.7M | 1.7x | 6.2x |
Eco Animal Health Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £1 | $27.0M | 0.2x | 2.9x |
Provexis | United Kingdom of Great Britain and Northern Ireland | Nutraceuticals & Cosmeceuticals | £0 | $14.5M | N/A | N/A |
Eden Research | United Kingdom of Great Britain and Northern Ireland | Agriculture, Bioindustrials | £0 | $12.7M | 2.2x | -7.8x |
Celadon Pharma | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Cannabis | £0 | $11.9M | N/A | N/A |
PureTech Health | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Biopharmaceuticals | £1 | -$109M | N/A | 0.8x |
Valuation multiples as of last 12 months (LTM). Stock prices as of April 15, 2025. Financial data powered by Morningstar and FactSet.
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.